Executive Summary
- •They expect to sell 7.8 million shares priced between $15 and $17.
- •For their lead molecule BH-30643, they've earmarked $70 million of the IPO cash—a massive allocation strictly necessary to push the drug through ongoing phase 1/2 trials against intense market competition.
- •But they aren't broke. The company entered April with 63 employees and $116 million in the bank.
Community Sentiment
Key Developments & Data
BlossomHill Therapeutics plans a $111.7 million IPO to challenge AstraZeneca $AZN blockbuster Tagrisso.
They expect to sell 7.8 million shares priced between $15 and $17.
For their lead molecule BH-30643, they've earmarked $70 million of the IPO cash—a massive allocation strictly necessary to push the drug through ongoing phase 1/2 trials against intense market competition.
But they aren't broke. The company entered April with 63 employees and $116 million in the bank.
Zubiqo Intelligence Briefing
Get the unfiltered signal before markets open.
Top tech breakthroughs, venture funding, and market moves—synthesized into a 2-minute morning read. Zero PR fluff.
✓ 100% Free•✓ 1-click unsubscribe•✓ No spam ever
